Arrowhead Corp (ARWR): Price-to-Projected Revenue Ratio

Arrowhead Pharmaceuticals (ARWR) - corporate logo

Arrowhead Pharmaceuticals (ARWR) relies on its unique TRiM platform for the precise suppression of pathogenic genes. The forward price-to-sales valuation reflects the dynamics of this advantage, with the latest value recorded as 15.00. Diversification of development in cardiology and pulmonology minimizes investment risks, while a neutral geopolitical status in the US ensures the stability of the company's research and development processes.

ARWR Arrowhead Pharmaceuticals, Inc.: Forward Price to Sales in the range 07/04/2022 - 11/14/2026

Summary analytical data breakdowns for Arrowhead Corp (ARWR)

- current price and projected stock value:
Stock Price Arrowhead Pharmaceuticals, Inc.|ARWR - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Arrowhead Corp|ARWR - Value Adjusted for Debt and Cash
- book value of equity indicators:
Net Assets per Single Share Arrowhead Pharmaceuticals|ARWR - Accounting Value of Company|Market Value to Book Value Ratio arrowheadpharma.com|ARWR - Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Arrowhead Pharmaceuticals|ARWR - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Arrowhead Pharmaceuticals|ARWR - Aggregate Debt Obligations|Debts to Book Capitalization Arrowhead Corp|ARWR - Long-Term Debt|Company Short-Term Debts Arrowhead Pharmaceuticals|Quick Ratio arrowheadpharma.com
- business earnings and investment ratios data:
ARWR - Company Profit|Future Profit Arrowhead Pharmaceuticals|ARWR - Company Value to Net Income|Future Price to Earnings Arrowhead Pharmaceuticals Inc|ARWR - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Arrowhead Corp|ARWR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Arrowhead Pharmaceuticals|ARWR - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months arrowheadpharma.com|ARWR - Earnings per share increase in current year|Net earnings per share growth forecast for next year Arrowhead Pharmaceuticals
- company sales and revenue statistics:
ARWR - Company Sales|Projected Sales Volume Arrowhead Pharmaceuticals, Inc.|ARWR - P/S Multiple|Forward P/S Multiple Arrowhead Corp
Summary company analysis:Arrowhead Pharmaceuticals, Inc. ARWR
Manufactured products of Arrowhead Corp

This indicator is calculated as the ratio of current market capitalization to projected revenue, allowing investors to assess the market discount or premium relative to future cash flows. By analyzing the forward P/S of the business, one can determine the valuation stability of Arrowhead Pharmaceuticals (ARWR), whose leadership in RNA interference and breakthrough liver disease treatments are driving elevated market expectations for future sales.

Competitor analysis

Forward P/S Multiple MIRM (Mirum)|Forward P/S Multiple Dynavax Corp DVAX|ABUS - Price-to-Projected Revenue Ratio|Forward Price to Sales IVA (Inventiva Corp)|Gyre Therapeutics, Inc. (GYRE) - Price-to-Projected Revenue Ratio|assemblybio.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Galectin Therapeutics, Inc.|Market Cap to Future Revenue Ratio Genfit Corp GNFT|Forward Price-to-Revenue Multiple DRRX (DURECT Corporation)|Forward Price-to-Revenue Multiple aligos.com ALGS|Forward P/S Multiple BIVI (BioVie)|Forward Price to Sales GLMD|ENDRA Life Sciences Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Hepion Pharmaceuticals